ALZN.O Falls Below 5-Day SMA Amid Trial Completion News
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 Nov 25
Source: Coinmarketcap
Shares of Alzamend Neuro (ALZN.O) declined sharply today, crossing below the 5-day simple moving average (SMA), indicating a potential shift towards bearish momentum. This movement follows the completion of the clinical portion of its Phase II trial for AL001, a novel lithium-delivery system designed to enhance treatment for Alzheimer's and other mental health disorders. While the trial utilized innovative imaging technology for precise lithium quantification, the market reacted cautiously, awaiting topline data expected in early 2026. Investors are now focused on the implications of this trial's results and the future of Alzamend's drug candidates, including ALZN002, which targets amyloid-beta proteins.
Analyst Views on ALZN
Wall Street analysts forecast ALZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALZN is 28.00 USD with a low forecast of 28.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.160
Low
28.00
Averages
28.00
High
28.00
Current: 2.160
Low
28.00
Averages
28.00
High
28.00
About ALZN
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
